Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Stellar Biotechnologies Announces pre-IDE Meeting with FDA

Abstract:
Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) announces the completion of a pre-Investigational Device Exemption (pre-IDE) meeting with the U.S. Food and Drug Administration's (FDA) Office of In Vitro Diagnostic Device Evaluation and Safety, Center for Devices and Radiological Health to discuss Stellar's proposed anti-KLH assay currently in development.

Stellar Biotechnologies Announces pre-IDE Meeting with FDA

Port Hueneme, CA | Posted on May 10th, 2011

The outcome of this consultation with the FDA assisted Stellar to identify and define its strategy to complete the clinical development and regulatory pathway for the anti-KLH in vitro diagnostic device. The FDA encouraged Stellar to consider additional clinical investigation plans that may distinguish the clinical correlation of the assay results with measures of patient immune response.

Stellar is committed to pursuing this unmet medical need to make this diagnostic tool available to clinicians as quickly as possible, and will work to complete the development and regulatory activities identified during this meeting with the Agency.

####

About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) (www.StellarBiotechnologies.com) is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.

For more information, please click here

Contacts:
Darrell Brookstein
Executive VP

Copyright © Stellar Biotechnologies, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Fine felted nanotubes : Research team of Kiel University develops new composite material made of carbon nanotubes November 22nd, 2017

Report highlights opportunities and risks associated with synthetic biology and bioengineering November 22nd, 2017

Quantum optics allows us to abandon expensive lasers in spectroscopy: Lomonosov Moscow State University scientists have invented a new method of spectroscopy November 21st, 2017

Nano-watch has steady hands November 21st, 2017

Govt.-Legislation/Regulation/Funding/Policy

EC Project Aims at Creating and Commercializing Cyber-Physical-System Solutions November 14th, 2017

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3ís significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Leti Joins DARPA-Funded Project to Develop Implantable Device for Restoring Vision November 9th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Nanomedicine

Fine felted nanotubes : Research team of Kiel University develops new composite material made of carbon nanotubes November 22nd, 2017

Nanoparticles could allow for faster, better medicine: Exposure of nanoparticles in the body allows for more effective delivery November 20th, 2017

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3ís significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

Announcements

Fine felted nanotubes : Research team of Kiel University develops new composite material made of carbon nanotubes November 22nd, 2017

Report highlights opportunities and risks associated with synthetic biology and bioengineering November 22nd, 2017

Quantum optics allows us to abandon expensive lasers in spectroscopy: Lomonosov Moscow State University scientists have invented a new method of spectroscopy November 21st, 2017

Nano-watch has steady hands November 21st, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project